Stem definition | Drug id | CAS RN |
---|---|---|
N-methylated xanthine derivatives | 2620 | 58-55-9 |
Dose | Unit | Route |
---|---|---|
0.40 | g | O |
0.40 | g | P |
0.40 | g | R |
0.60 | g | O |
0.60 | g | P |
0.60 | g | R |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 8.30 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 18 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 48.12 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.51 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.86 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.61 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 7.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 19, 1940 | FDA | GD SEARLE LLC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 531.57 | 12.42 | 387 | 22428 | 88950 | 50493359 |
Wheezing | 417.69 | 12.42 | 290 | 22525 | 61757 | 50520552 |
Chronic obstructive pulmonary disease | 165.54 | 12.42 | 159 | 22656 | 53276 | 50529033 |
Productive cough | 163.62 | 12.42 | 157 | 22658 | 52537 | 50529772 |
Dyspnoea | 161.27 | 12.42 | 576 | 22239 | 547032 | 50035277 |
Sputum discoloured | 127.71 | 12.42 | 78 | 22737 | 13317 | 50568992 |
Breath sounds abnormal | 119.57 | 12.42 | 62 | 22753 | 7730 | 50574579 |
Forced expiratory volume decreased | 113.45 | 12.42 | 50 | 22765 | 4344 | 50577965 |
Rales | 113.17 | 12.42 | 65 | 22750 | 9913 | 50572396 |
Sinus tachycardia | 112.07 | 12.42 | 86 | 22729 | 21268 | 50561041 |
Bronchial neoplasm | 96.52 | 12.42 | 25 | 22790 | 408 | 50581901 |
Chest discomfort | 94.18 | 12.42 | 158 | 22657 | 92564 | 50489745 |
Bronchial haemorrhage | 91.98 | 12.42 | 25 | 22790 | 495 | 50581814 |
Nasal turbinate hypertrophy | 90.15 | 12.42 | 26 | 22789 | 644 | 50581665 |
Nasal congestion | 80.48 | 12.42 | 107 | 22708 | 51013 | 50531296 |
Endometrial ablation | 79.47 | 12.42 | 25 | 22790 | 838 | 50581471 |
Sleep disorder due to a general medical condition | 78.24 | 12.42 | 46 | 22769 | 7325 | 50574984 |
Hypercapnia | 77.32 | 12.42 | 39 | 22776 | 4588 | 50577721 |
Cough | 76.73 | 12.42 | 261 | 22554 | 241003 | 50341306 |
Bronchial disorder | 76.50 | 12.42 | 26 | 22789 | 1116 | 50581193 |
Obstructive airways disorder | 75.54 | 12.42 | 60 | 22755 | 15592 | 50566717 |
Rhonchi | 71.92 | 12.42 | 30 | 22785 | 2277 | 50580032 |
Prolonged expiration | 66.87 | 12.42 | 21 | 22794 | 700 | 50581609 |
Heart sounds | 65.38 | 12.42 | 20 | 22795 | 610 | 50581699 |
Status asthmaticus | 63.89 | 12.42 | 21 | 22794 | 812 | 50581497 |
Alopecia | 61.85 | 12.42 | 17 | 22798 | 245030 | 50337279 |
Bronchitis chronic | 57.05 | 12.42 | 30 | 22785 | 3847 | 50578462 |
Pulmonary pain | 55.46 | 12.42 | 25 | 22790 | 2290 | 50580019 |
Neurosensory hypoacusis | 54.97 | 12.42 | 14 | 22801 | 213 | 50582096 |
Systemic lupus erythematosus | 51.33 | 12.42 | 3 | 22812 | 140619 | 50441690 |
Pneumonia | 49.24 | 12.42 | 315 | 22500 | 378086 | 50204223 |
Joint swelling | 48.57 | 12.42 | 25 | 22790 | 245261 | 50337048 |
Rheumatoid arthritis | 47.58 | 12.42 | 16 | 22799 | 202534 | 50379775 |
Rhinitis | 47.01 | 12.42 | 35 | 22780 | 8266 | 50574043 |
Occupational asthma | 46.90 | 12.42 | 11 | 22804 | 116 | 50582193 |
Lower respiratory tract infection | 46.43 | 12.42 | 120 | 22695 | 95081 | 50487228 |
Toxicity to various agents | 46.25 | 12.42 | 204 | 22611 | 212295 | 50370014 |
Granuloma | 45.56 | 12.42 | 28 | 22787 | 4830 | 50577479 |
Respiratory rate increased | 45.25 | 12.42 | 39 | 22776 | 11346 | 50570963 |
Airway peak pressure increased | 42.16 | 12.42 | 12 | 22803 | 283 | 50582026 |
Treatment failure | 42.10 | 12.42 | 6 | 22809 | 137631 | 50444678 |
Bronchospasm | 41.84 | 12.42 | 42 | 22773 | 14812 | 50567497 |
Depressed mood | 41.39 | 12.42 | 63 | 22752 | 33960 | 50548349 |
Dyspnoea exertional | 41.31 | 12.42 | 79 | 22736 | 51154 | 50531155 |
Multiple drug therapy | 40.40 | 12.42 | 19 | 22796 | 1918 | 50580391 |
Respiratory acidosis | 40.04 | 12.42 | 28 | 22787 | 6000 | 50576309 |
Drug interaction | 39.96 | 12.42 | 187 | 22628 | 199434 | 50382875 |
Lung hyperinflation | 39.83 | 12.42 | 16 | 22799 | 1102 | 50581207 |
PCO2 increased | 39.49 | 12.42 | 16 | 22799 | 1127 | 50581182 |
Middle insomnia | 39.46 | 12.42 | 34 | 22781 | 9887 | 50572422 |
Depressive symptom | 39.39 | 12.42 | 22 | 22793 | 3178 | 50579131 |
Pain | 39.38 | 12.42 | 132 | 22683 | 578771 | 50003538 |
Respiration abnormal | 39.37 | 12.42 | 26 | 22789 | 5076 | 50577233 |
Increased viscosity of bronchial secretion | 39.04 | 12.42 | 11 | 22804 | 250 | 50582059 |
Affective disorder | 39.00 | 12.42 | 26 | 22789 | 5155 | 50577154 |
Fatigue | 38.79 | 12.42 | 176 | 22639 | 707425 | 49874884 |
Exercise tolerance decreased | 38.00 | 12.42 | 25 | 22790 | 4849 | 50577460 |
Bronchial obstruction | 37.62 | 12.42 | 16 | 22799 | 1274 | 50581035 |
Acute respiratory failure | 37.45 | 12.42 | 55 | 22760 | 28727 | 50553582 |
Lipohypertrophy | 37.34 | 12.42 | 13 | 22802 | 600 | 50581709 |
Eosinophil count increased | 36.62 | 12.42 | 31 | 22784 | 8799 | 50573510 |
Oesophageal dilatation | 36.39 | 12.42 | 11 | 22804 | 322 | 50581987 |
Decreased bronchial secretion | 36.20 | 12.42 | 8 | 22807 | 63 | 50582246 |
Infusion related reaction | 35.50 | 12.42 | 16 | 22799 | 169541 | 50412768 |
Congestive cardiomyopathy | 35.19 | 12.42 | 25 | 22790 | 5493 | 50576816 |
Off label use | 35.17 | 12.42 | 104 | 22711 | 474322 | 50107987 |
Respiratory tract inflammation | 35.02 | 12.42 | 12 | 22803 | 528 | 50581781 |
Rash | 34.56 | 12.42 | 93 | 22722 | 437378 | 50144931 |
Eosinophilic granulomatosis with polyangiitis | 34.20 | 12.42 | 17 | 22798 | 1938 | 50580371 |
Respiratory disorder | 34.12 | 12.42 | 55 | 22760 | 31132 | 50551177 |
Swelling | 33.48 | 12.42 | 25 | 22790 | 200847 | 50381462 |
PO2 decreased | 33.36 | 12.42 | 15 | 22800 | 1366 | 50580943 |
Blood pressure inadequately controlled | 33.02 | 12.42 | 22 | 22793 | 4358 | 50577951 |
Adrenal suppression | 32.88 | 12.42 | 13 | 22802 | 859 | 50581450 |
Contraindicated product administered | 32.87 | 12.42 | 13 | 22802 | 148945 | 50433364 |
Synovitis | 32.35 | 12.42 | 8 | 22807 | 123857 | 50458452 |
Drug ineffective | 32.31 | 12.42 | 227 | 22588 | 819106 | 49763203 |
Arteriosclerosis coronary artery | 32.06 | 12.42 | 27 | 22788 | 7609 | 50574700 |
Hepatic enzyme increased | 31.98 | 12.42 | 11 | 22804 | 137369 | 50444940 |
Respiratory failure | 31.88 | 12.42 | 102 | 22713 | 91079 | 50491230 |
Emphysema | 31.85 | 12.42 | 29 | 22786 | 9064 | 50573245 |
Vital capacity decreased | 31.72 | 12.42 | 13 | 22802 | 943 | 50581366 |
Tachycardia | 31.67 | 12.42 | 108 | 22707 | 99655 | 50482654 |
Female sterilisation | 31.65 | 12.42 | 11 | 22804 | 505 | 50581804 |
Stress cardiomyopathy | 31.30 | 12.42 | 27 | 22788 | 7860 | 50574449 |
Asthmatic crisis | 31.00 | 12.42 | 15 | 22800 | 1613 | 50580696 |
Blood bicarbonate decreased | 28.90 | 12.42 | 17 | 22798 | 2708 | 50579601 |
Ligament pain | 28.38 | 12.42 | 8 | 22807 | 182 | 50582127 |
Blood pH decreased | 27.85 | 12.42 | 16 | 22799 | 2439 | 50579870 |
Breast neoplasm | 27.76 | 12.42 | 13 | 22802 | 1300 | 50581009 |
Viral infection | 27.65 | 12.42 | 49 | 22766 | 29937 | 50552372 |
Arthropathy | 27.15 | 12.42 | 19 | 22796 | 157887 | 50424422 |
Product use issue | 27.03 | 12.42 | 17 | 22798 | 149458 | 50432851 |
Drug level increased | 26.79 | 12.42 | 38 | 22777 | 19230 | 50563079 |
Dyspnoea at rest | 26.73 | 12.42 | 18 | 22797 | 3629 | 50578680 |
Drug intolerance | 26.53 | 12.42 | 36 | 22779 | 219068 | 50363241 |
Left ventricular failure | 26.49 | 12.42 | 20 | 22795 | 4821 | 50577488 |
Appetite disorder | 26.46 | 12.42 | 22 | 22793 | 6092 | 50576217 |
Sinus pain | 26.36 | 12.42 | 15 | 22800 | 2246 | 50580063 |
Oligoarthritis | 26.34 | 12.42 | 8 | 22807 | 238 | 50582071 |
Eosinophilia | 26.25 | 12.42 | 37 | 22778 | 18615 | 50563694 |
Rhinorrhoea | 26.14 | 12.42 | 66 | 22749 | 51517 | 50530792 |
Drug level above therapeutic | 25.55 | 12.42 | 18 | 22797 | 3902 | 50578407 |
Therapeutic product effect decreased | 25.26 | 12.42 | 15 | 22800 | 136035 | 50446274 |
Diabetes mellitus | 25.12 | 12.42 | 63 | 22752 | 48970 | 50533339 |
Heart rate increased | 24.84 | 12.42 | 84 | 22731 | 77166 | 50505143 |
Oxygen saturation decreased | 24.75 | 12.42 | 81 | 22734 | 73167 | 50509142 |
Diabetes mellitus inadequate control | 24.59 | 12.42 | 30 | 22785 | 13115 | 50569194 |
Respiratory tract congestion | 24.32 | 12.42 | 31 | 22784 | 14168 | 50568141 |
Full blood count abnormal | 23.90 | 12.42 | 40 | 22775 | 23348 | 50558961 |
Infective exacerbation of chronic obstructive airways disease | 23.51 | 12.42 | 11 | 22804 | 1097 | 50581212 |
Kyphosis | 23.51 | 12.42 | 14 | 22801 | 2281 | 50580028 |
Oesophagogastroduodenoscopy | 23.27 | 12.42 | 6 | 22809 | 96 | 50582213 |
Hypoventilation | 23.25 | 12.42 | 17 | 22798 | 3904 | 50578405 |
Painful respiration | 23.06 | 12.42 | 14 | 22801 | 2361 | 50579948 |
Abdominal discomfort | 22.48 | 12.42 | 44 | 22771 | 231597 | 50350712 |
Febrile neutropenia | 22.42 | 12.42 | 8 | 22807 | 97659 | 50484650 |
Pertussis | 22.28 | 12.42 | 9 | 22806 | 629 | 50581680 |
Urogenital haemorrhage | 22.18 | 12.42 | 7 | 22808 | 237 | 50582072 |
Spleen congestion | 22.11 | 12.42 | 6 | 22809 | 118 | 50582191 |
Rhabdomyolysis | 21.97 | 12.42 | 52 | 22763 | 38975 | 50543334 |
Blood lactic acid increased | 21.92 | 12.42 | 19 | 22796 | 5566 | 50576743 |
Pleural rub | 21.84 | 12.42 | 5 | 22810 | 47 | 50582262 |
Macrocytosis | 21.83 | 12.42 | 13 | 22802 | 2117 | 50580192 |
Glossitis | 21.63 | 12.42 | 14 | 22801 | 2641 | 50579668 |
Neutropenia | 21.48 | 12.42 | 21 | 22794 | 147944 | 50434365 |
Completed suicide | 21.22 | 12.42 | 17 | 22798 | 131872 | 50450437 |
Eye paraesthesia | 21.21 | 12.42 | 5 | 22810 | 54 | 50582255 |
Cyanosis | 21.19 | 12.42 | 30 | 22785 | 15154 | 50567155 |
Presbyacusis | 21.06 | 12.42 | 14 | 22801 | 2762 | 50579547 |
Blood immunoglobulin E increased | 20.61 | 12.42 | 13 | 22802 | 2346 | 50579963 |
Tremor | 20.35 | 12.42 | 104 | 22711 | 114799 | 50467510 |
Diarrhoea | 20.30 | 12.42 | 169 | 22646 | 588307 | 49994002 |
Influenza | 20.22 | 12.42 | 87 | 22728 | 89451 | 50492858 |
Medication error | 20.21 | 12.42 | 48 | 22767 | 36056 | 50546253 |
Lung opacity | 20.12 | 12.42 | 12 | 22803 | 1961 | 50580348 |
Antasthmatic drug level above therapeutic | 20.12 | 12.42 | 3 | 22812 | 0 | 50582309 |
Discomfort | 20.04 | 12.42 | 12 | 22803 | 108368 | 50473941 |
Paranasal sinus hypersecretion | 19.49 | 12.42 | 14 | 22801 | 3128 | 50579181 |
Myopathy | 18.98 | 12.42 | 22 | 22793 | 9117 | 50573192 |
Ankle fracture | 18.96 | 12.42 | 29 | 22786 | 15693 | 50566616 |
Musculoskeletal stiffness | 18.92 | 12.42 | 18 | 22797 | 128463 | 50453846 |
Ventricular tachycardia | 18.82 | 12.42 | 29 | 22786 | 15792 | 50566517 |
Hypokalaemia | 17.99 | 12.42 | 83 | 22732 | 87909 | 50494400 |
Haemoptysis | 17.69 | 12.42 | 37 | 22778 | 25536 | 50556773 |
Allergic cough | 17.68 | 12.42 | 7 | 22808 | 464 | 50581845 |
Stomatitis | 17.67 | 12.42 | 12 | 22803 | 101332 | 50480977 |
Bronchitis | 17.55 | 12.42 | 93 | 22722 | 104066 | 50478243 |
Respiratory tract infection | 17.31 | 12.42 | 42 | 22773 | 31975 | 50550334 |
Impaired healing | 17.28 | 12.42 | 5 | 22810 | 69781 | 50512528 |
Increased bronchial secretion | 17.24 | 12.42 | 10 | 22805 | 1552 | 50580757 |
Depressed level of consciousness | 17.14 | 12.42 | 57 | 22758 | 51896 | 50530413 |
Stress urinary incontinence | 17.10 | 12.42 | 11 | 22804 | 2054 | 50580255 |
Nasal oedema | 16.88 | 12.42 | 8 | 22807 | 822 | 50581487 |
Pulmonary congestion | 16.82 | 12.42 | 27 | 22788 | 15220 | 50567089 |
Anaphylactic reaction | 16.69 | 12.42 | 58 | 22757 | 53997 | 50528312 |
Crepitations | 16.45 | 12.42 | 17 | 22798 | 6202 | 50576107 |
Seizure | 16.41 | 12.42 | 100 | 22715 | 117774 | 50464535 |
Staphylococcus test positive | 16.31 | 12.42 | 13 | 22802 | 3393 | 50578916 |
Glaucoma | 16.25 | 12.42 | 27 | 22788 | 15659 | 50566650 |
Hypercholesterolaemia | 16.15 | 12.42 | 23 | 22792 | 11680 | 50570629 |
Food allergy | 15.92 | 12.42 | 19 | 22796 | 8118 | 50574191 |
Flail chest | 15.88 | 12.42 | 4 | 22811 | 58 | 50582251 |
Chest pain | 15.88 | 12.42 | 135 | 22680 | 176747 | 50405562 |
Oropharyngeal candidiasis | 15.71 | 12.42 | 8 | 22807 | 960 | 50581349 |
Cushingoid | 15.51 | 12.42 | 17 | 22798 | 6628 | 50575681 |
Injection site hypoaesthesia | 15.48 | 12.42 | 6 | 22809 | 376 | 50581933 |
Lung perforation | 15.40 | 12.42 | 4 | 22811 | 66 | 50582243 |
Peripheral swelling | 15.30 | 12.42 | 45 | 22770 | 205891 | 50376418 |
Status epilepticus | 15.15 | 12.42 | 24 | 22791 | 13382 | 50568927 |
Aortic valve calcification | 15.11 | 12.42 | 6 | 22809 | 401 | 50581908 |
Generalised tonic-clonic seizure | 14.75 | 12.42 | 35 | 22780 | 26275 | 50556034 |
Mental disability | 14.49 | 12.42 | 4 | 22811 | 84 | 50582225 |
Atopy | 14.48 | 12.42 | 5 | 22810 | 225 | 50582084 |
Escherichia infection | 14.36 | 12.42 | 21 | 22794 | 10920 | 50571389 |
Contraindicated product prescribed | 14.15 | 12.42 | 7 | 22808 | 790 | 50581519 |
Sputum abnormal | 14.13 | 12.42 | 6 | 22809 | 476 | 50581833 |
Dysphonia | 14.03 | 12.42 | 44 | 22771 | 38848 | 50543461 |
Scratch | 13.91 | 12.42 | 14 | 22801 | 4948 | 50577361 |
Parakeratosis | 13.75 | 12.42 | 5 | 22810 | 262 | 50582047 |
Injection site pain | 13.67 | 12.42 | 18 | 22797 | 111006 | 50471303 |
White blood cell count increased | 13.63 | 12.42 | 46 | 22769 | 42194 | 50540115 |
Intentional product use issue | 13.55 | 12.42 | 9 | 22806 | 76909 | 50505400 |
Seasonal allergy | 13.55 | 12.42 | 24 | 22791 | 14652 | 50567657 |
Tendon pain | 13.48 | 12.42 | 11 | 22804 | 2967 | 50579342 |
Disease progression | 13.46 | 12.42 | 14 | 22801 | 95852 | 50486457 |
Upper respiratory tract infection | 13.34 | 12.42 | 62 | 22753 | 65836 | 50516473 |
White blood cell count decreased | 13.30 | 12.42 | 20 | 22795 | 116702 | 50465607 |
Galactorrhoea | 13.29 | 12.42 | 12 | 22803 | 3711 | 50578598 |
Respiratory symptom | 13.27 | 12.42 | 10 | 22805 | 2404 | 50579905 |
Supraventricular tachycardia | 13.22 | 12.42 | 22 | 22793 | 12779 | 50569530 |
Vasodilation procedure | 13.12 | 12.42 | 3 | 22812 | 28 | 50582281 |
Blood prolactin increased | 13.10 | 12.42 | 11 | 22804 | 3088 | 50579221 |
Anaemia | 13.03 | 12.42 | 64 | 22751 | 252392 | 50329917 |
Thoracic operation | 12.98 | 12.42 | 4 | 22811 | 125 | 50582184 |
Hyperventilation | 12.91 | 12.42 | 14 | 22801 | 5395 | 50576914 |
Amnestic disorder | 12.89 | 12.42 | 5 | 22810 | 314 | 50581995 |
Weaning failure | 12.84 | 12.42 | 5 | 22810 | 317 | 50581992 |
Atrial fibrillation | 12.72 | 12.42 | 84 | 22731 | 101661 | 50480648 |
Hallucination, visual | 12.66 | 12.42 | 25 | 22790 | 16557 | 50565752 |
Haemoglobin decreased | 12.47 | 12.42 | 24 | 22791 | 127192 | 50455117 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 544.40 | 13.81 | 289 | 14832 | 33560 | 29525846 |
Wheezing | 248.56 | 13.81 | 174 | 14947 | 33066 | 29526340 |
Chronic obstructive pulmonary disease | 209.79 | 13.81 | 171 | 14950 | 40784 | 29518622 |
Obstructive airways disorder | 162.51 | 13.81 | 89 | 15032 | 10927 | 29548479 |
Forced expiratory volume decreased | 143.31 | 13.81 | 54 | 15067 | 2759 | 29556647 |
Dyspnoea | 126.24 | 13.81 | 409 | 14712 | 326323 | 29233083 |
Right atrial hypertrophy | 120.28 | 13.81 | 32 | 15089 | 510 | 29558896 |
Bronchial wall thickening | 107.56 | 13.81 | 34 | 15087 | 1018 | 29558388 |
Productive cough | 105.15 | 13.81 | 103 | 15018 | 31156 | 29528250 |
Bronchial secretion retention | 104.49 | 13.81 | 34 | 15087 | 1119 | 29558287 |
Full blood count abnormal | 103.78 | 13.81 | 75 | 15046 | 14938 | 29544468 |
Right ventricular hypertrophy | 96.22 | 13.81 | 32 | 15089 | 1129 | 29558277 |
Therapeutic product effect incomplete | 88.95 | 13.81 | 105 | 15016 | 39200 | 29520206 |
Obstruction | 87.44 | 13.81 | 34 | 15087 | 1892 | 29557514 |
Aortic valve stenosis | 82.94 | 13.81 | 34 | 15087 | 2174 | 29557232 |
Pulmonary function test abnormal | 81.42 | 13.81 | 33 | 15088 | 2049 | 29557357 |
Vital capacity decreased | 78.68 | 13.81 | 21 | 15100 | 339 | 29559067 |
Sleep disorder due to a general medical condition | 77.54 | 13.81 | 36 | 15085 | 3110 | 29556296 |
Loss of personal independence in daily activities | 71.30 | 13.81 | 76 | 15045 | 25364 | 29534042 |
Chest X-ray abnormal | 71.13 | 13.81 | 36 | 15085 | 3758 | 29555648 |
Diastolic dysfunction | 66.71 | 13.81 | 38 | 15083 | 5026 | 29554380 |
Gastrooesophageal reflux disease | 66.09 | 13.81 | 81 | 15040 | 31415 | 29527991 |
Cough | 65.08 | 13.81 | 176 | 14945 | 126551 | 29432855 |
Intervertebral disc degeneration | 60.09 | 13.81 | 36 | 15085 | 5228 | 29554178 |
Sputum discoloured | 57.62 | 13.81 | 38 | 15083 | 6525 | 29552881 |
Bronchiectasis | 55.09 | 13.81 | 37 | 15084 | 6548 | 29552858 |
Foetal malformation | 54.89 | 13.81 | 13 | 15108 | 125 | 29559281 |
Rhinitis perennial | 53.78 | 13.81 | 14 | 15107 | 204 | 29559202 |
Respiratory failure | 51.94 | 13.81 | 137 | 14984 | 96994 | 29462412 |
Mental disability | 51.70 | 13.81 | 10 | 15111 | 31 | 29559375 |
Trisomy 18 | 50.36 | 13.81 | 13 | 15108 | 183 | 29559223 |
Forced vital capacity decreased | 49.95 | 13.81 | 17 | 15104 | 644 | 29558762 |
Pulmonary function test decreased | 48.90 | 13.81 | 29 | 15092 | 4134 | 29555272 |
Osteoporosis | 48.89 | 13.81 | 42 | 15079 | 10727 | 29548679 |
Eosinophil count increased | 40.25 | 13.81 | 32 | 15089 | 7337 | 29552069 |
Benign prostatic hyperplasia | 40.11 | 13.81 | 39 | 15082 | 11671 | 29547735 |
Atrial fibrillation | 38.38 | 13.81 | 130 | 14991 | 105516 | 29453890 |
Chest discomfort | 37.96 | 13.81 | 77 | 15044 | 45906 | 29513500 |
Gout | 36.28 | 13.81 | 44 | 15077 | 16867 | 29542539 |
Supraventricular tachycardia | 35.90 | 13.81 | 34 | 15087 | 9850 | 29549556 |
Total lung capacity abnormal | 34.91 | 13.81 | 9 | 15112 | 126 | 29559280 |
Eosinophilic granulomatosis with polyangiitis | 34.59 | 13.81 | 16 | 15105 | 1370 | 29558036 |
Ocular discomfort | 34.53 | 13.81 | 17 | 15104 | 1672 | 29557734 |
Sleep apnoea syndrome | 33.30 | 13.81 | 43 | 15078 | 17556 | 29541850 |
Adjustment disorder | 32.84 | 13.81 | 14 | 15107 | 987 | 29558419 |
Emphysema | 29.92 | 13.81 | 29 | 15092 | 8642 | 29550764 |
Off label use | 29.73 | 13.81 | 69 | 15052 | 300731 | 29258675 |
Seasonal allergy | 29.69 | 13.81 | 23 | 15098 | 5079 | 29554327 |
Dyspnoea exertional | 28.80 | 13.81 | 60 | 15061 | 36430 | 29522976 |
Tachycardia foetal | 28.38 | 13.81 | 9 | 15112 | 272 | 29559134 |
Eosinophilic bronchitis | 27.90 | 13.81 | 8 | 15113 | 170 | 29559236 |
Sputum increased | 26.84 | 13.81 | 15 | 15106 | 1912 | 29557494 |
Wolff-Parkinson-White syndrome | 26.79 | 13.81 | 8 | 15113 | 197 | 29559209 |
Blood immunoglobulin E increased | 26.69 | 13.81 | 15 | 15106 | 1932 | 29557474 |
Hypercapnia | 26.61 | 13.81 | 19 | 15102 | 3707 | 29555699 |
Foetal distress syndrome | 26.40 | 13.81 | 12 | 15109 | 987 | 29558419 |
Lung hyperinflation | 25.47 | 13.81 | 11 | 15110 | 801 | 29558605 |
Hypoacusis | 25.36 | 13.81 | 34 | 15087 | 14389 | 29545017 |
Tachycardia | 25.30 | 13.81 | 88 | 15033 | 72322 | 29487084 |
Diarrhoea | 24.33 | 13.81 | 88 | 15033 | 332610 | 29226796 |
Anxiety | 24.21 | 13.81 | 97 | 15024 | 85268 | 29474138 |
Pneumonia | 23.83 | 13.81 | 259 | 14862 | 319913 | 29239493 |
Febrile neutropenia | 23.70 | 13.81 | 14 | 15107 | 112226 | 29447180 |
Dermatitis allergic | 23.44 | 13.81 | 21 | 15100 | 5667 | 29553739 |
Bronchial obstruction | 22.62 | 13.81 | 12 | 15109 | 1379 | 29558027 |
Hypoxia | 22.46 | 13.81 | 64 | 15057 | 47315 | 29512091 |
Conduction disorder | 22.08 | 13.81 | 13 | 15108 | 1827 | 29557579 |
Neutropenia | 21.94 | 13.81 | 21 | 15100 | 131690 | 29427716 |
Arrhythmia | 21.86 | 13.81 | 49 | 15072 | 31264 | 29528142 |
Drug level increased | 21.19 | 13.81 | 36 | 15085 | 18751 | 29540655 |
Supraventricular extrasystoles | 21.01 | 13.81 | 15 | 15106 | 2926 | 29556480 |
Tachyarrhythmia | 20.88 | 13.81 | 15 | 15106 | 2954 | 29556452 |
Eye pruritus | 19.87 | 13.81 | 17 | 15104 | 4315 | 29555091 |
Pancytopenia | 19.58 | 13.81 | 9 | 15112 | 83159 | 29476247 |
Product use in unapproved indication | 19.55 | 13.81 | 10 | 15111 | 86865 | 29472541 |
Lung diffusion disorder | 18.66 | 13.81 | 5 | 15116 | 82 | 29559324 |
Obesity | 18.50 | 13.81 | 24 | 15097 | 9839 | 29549567 |
Perfume sensitivity | 18.33 | 13.81 | 5 | 15116 | 88 | 29559318 |
Tonic convulsion | 17.89 | 13.81 | 9 | 15112 | 927 | 29558479 |
Carbon dioxide increased | 17.55 | 13.81 | 9 | 15112 | 965 | 29558441 |
Dermatitis atopic | 17.44 | 13.81 | 12 | 15109 | 2207 | 29557199 |
Glaucoma | 17.29 | 13.81 | 18 | 15103 | 5839 | 29553567 |
Ventricular extrasystoles | 17.18 | 13.81 | 24 | 15097 | 10558 | 29548848 |
Pain | 17.15 | 13.81 | 39 | 15082 | 171393 | 29388013 |
Lung opacity | 17.14 | 13.81 | 10 | 15111 | 1382 | 29558024 |
Somnambulism | 17.12 | 13.81 | 13 | 15108 | 2785 | 29556621 |
Epidural lipomatosis | 17.10 | 13.81 | 8 | 15113 | 703 | 29558703 |
Unmasking of previously unidentified disease | 16.97 | 13.81 | 8 | 15113 | 715 | 29558691 |
Axial spondyloarthritis | 16.66 | 13.81 | 6 | 15115 | 269 | 29559137 |
Status asthmaticus | 16.31 | 13.81 | 6 | 15115 | 286 | 29559120 |
Gastrointestinal necrosis | 16.24 | 13.81 | 13 | 15108 | 3009 | 29556397 |
Lipid metabolism disorder | 15.89 | 13.81 | 6 | 15115 | 308 | 29559098 |
Acute kidney injury | 15.73 | 13.81 | 76 | 15045 | 265191 | 29294215 |
Eosinophilic pneumonia chronic | 15.44 | 13.81 | 5 | 15116 | 162 | 29559244 |
Vitamin D increased | 15.14 | 13.81 | 4 | 15117 | 62 | 29559344 |
Nikolsky's sign | 14.91 | 13.81 | 5 | 15116 | 181 | 29559225 |
Thrombocytopenia | 14.88 | 13.81 | 29 | 15092 | 134794 | 29424612 |
Loss of proprioception | 14.87 | 13.81 | 6 | 15115 | 368 | 29559038 |
Neuropathy peripheral | 14.79 | 13.81 | 9 | 15112 | 71018 | 29488388 |
Haemophilus infection | 14.77 | 13.81 | 8 | 15113 | 959 | 29558447 |
Oropharyngeal candidiasis | 14.64 | 13.81 | 7 | 15114 | 646 | 29558760 |
Hypercholesterolaemia | 14.18 | 13.81 | 18 | 15103 | 7220 | 29552186 |
Sputum purulent | 13.94 | 13.81 | 6 | 15115 | 433 | 29558973 |
Electrocardiogram repolarisation abnormality | 13.91 | 13.81 | 7 | 15114 | 721 | 29558685 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 811.65 | 12.23 | 544 | 33083 | 94681 | 64370424 |
Wheezing | 552.15 | 12.23 | 403 | 33224 | 80176 | 64384929 |
Chronic obstructive pulmonary disease | 308.17 | 12.23 | 272 | 33355 | 70776 | 64394329 |
Productive cough | 223.64 | 12.23 | 231 | 33396 | 72972 | 64392133 |
Forced expiratory volume decreased | 220.16 | 12.23 | 95 | 33532 | 6772 | 64458333 |
Dyspnoea | 206.33 | 12.23 | 828 | 32799 | 717846 | 63747259 |
Obstructive airways disorder | 181.64 | 12.23 | 126 | 33501 | 23059 | 64442046 |
Sputum discoloured | 137.42 | 12.23 | 96 | 33531 | 17760 | 64447345 |
Sleep disorder due to a general medical condition | 135.38 | 12.23 | 72 | 33555 | 8162 | 64456943 |
Right atrial hypertrophy | 119.47 | 12.23 | 32 | 33595 | 513 | 64464592 |
Cough | 108.48 | 12.23 | 375 | 33252 | 301773 | 64163332 |
Sinus tachycardia | 108.13 | 12.23 | 107 | 33520 | 32081 | 64433024 |
Breath sounds abnormal | 104.71 | 12.23 | 69 | 33558 | 11600 | 64453505 |
Bronchial wall thickening | 101.46 | 12.23 | 38 | 33589 | 1869 | 64463236 |
Rales | 94.75 | 12.23 | 72 | 33555 | 15157 | 64449948 |
Bronchial neoplasm | 92.35 | 12.23 | 25 | 33602 | 418 | 64464687 |
Right ventricular hypertrophy | 91.56 | 12.23 | 32 | 33595 | 1288 | 64463817 |
Obstruction | 91.38 | 12.23 | 41 | 33586 | 3207 | 64461898 |
Full blood count abnormal | 90.95 | 12.23 | 94 | 33533 | 29663 | 64435442 |
Chest discomfort | 90.42 | 12.23 | 192 | 33435 | 115914 | 64349191 |
Nasal turbinate hypertrophy | 85.90 | 12.23 | 25 | 33602 | 550 | 64464555 |
Nasal congestion | 85.75 | 12.23 | 129 | 33498 | 59529 | 64405576 |
Hypercapnia | 85.28 | 12.23 | 52 | 33575 | 7642 | 64457463 |
Bronchial secretion retention | 81.12 | 12.23 | 35 | 33592 | 2492 | 64462613 |
Endometrial ablation | 77.73 | 12.23 | 25 | 33602 | 776 | 64464329 |
Aortic valve stenosis | 72.34 | 12.23 | 39 | 33588 | 4541 | 64460564 |
Mental disability | 71.96 | 12.23 | 14 | 33613 | 44 | 64465061 |
Rhonchi | 70.58 | 12.23 | 35 | 33592 | 3428 | 64461677 |
Pulmonary function test abnormal | 70.54 | 12.23 | 34 | 33593 | 3130 | 64461975 |
Bronchial haemorrhage | 67.39 | 12.23 | 25 | 33602 | 1197 | 64463908 |
Eosinophil count increased | 67.09 | 12.23 | 57 | 33570 | 14055 | 64451050 |
Status asthmaticus | 65.36 | 12.23 | 23 | 33604 | 945 | 64464160 |
Pneumonia | 62.86 | 12.23 | 502 | 33125 | 559074 | 63906031 |
Loss of personal independence in daily activities | 62.47 | 12.23 | 125 | 33502 | 72329 | 64392776 |
Lung hyperinflation | 60.67 | 12.23 | 25 | 33602 | 1587 | 64463518 |
Bronchial disorder | 60.46 | 12.23 | 27 | 33600 | 2088 | 64463017 |
Respiratory failure | 59.41 | 12.23 | 202 | 33425 | 160981 | 64304124 |
Heart sounds | 59.25 | 12.23 | 19 | 33608 | 584 | 64464521 |
Rhinitis | 58.52 | 12.23 | 47 | 33580 | 10718 | 64454387 |
Pulmonary pain | 58.32 | 12.23 | 28 | 33599 | 2556 | 64462549 |
Therapeutic product effect incomplete | 56.45 | 12.23 | 149 | 33478 | 103333 | 64361772 |
Bronchial obstruction | 54.41 | 12.23 | 26 | 33601 | 2348 | 64462757 |
Prolonged expiration | 53.46 | 12.23 | 19 | 33608 | 804 | 64464301 |
Chest X-ray abnormal | 51.58 | 12.23 | 36 | 33591 | 6645 | 64458460 |
Emphysema | 51.42 | 12.23 | 49 | 33578 | 14020 | 64451085 |
Off label use | 51.00 | 12.23 | 165 | 33462 | 632641 | 63832464 |
Alopecia | 48.84 | 12.23 | 13 | 33614 | 165677 | 64299428 |
Neurosensory hypoacusis | 48.38 | 12.23 | 13 | 33614 | 211 | 64464894 |
Rhinitis perennial | 47.87 | 12.23 | 13 | 33614 | 220 | 64464885 |
Febrile neutropenia | 47.79 | 12.23 | 19 | 33608 | 187638 | 64277467 |
Atrial fibrillation | 47.67 | 12.23 | 196 | 33431 | 170893 | 64294212 |
Tachycardia | 47.03 | 12.23 | 178 | 33449 | 149401 | 64315704 |
Seasonal allergy | 47.01 | 12.23 | 43 | 33584 | 11683 | 64453422 |
Neutropenia | 46.81 | 12.23 | 34 | 33593 | 239590 | 64225515 |
Diastolic dysfunction | 46.66 | 12.23 | 38 | 33589 | 8837 | 64456268 |
Benign prostatic hyperplasia | 45.59 | 12.23 | 38 | 33589 | 9127 | 64455978 |
Lower respiratory tract infection | 45.40 | 12.23 | 130 | 33497 | 94484 | 64370621 |
Dyspnoea exertional | 45.23 | 12.23 | 111 | 33516 | 73619 | 64391486 |
Supraventricular tachycardia | 44.36 | 12.23 | 52 | 33575 | 18855 | 64446250 |
Eosinophilic granulomatosis with polyangiitis | 44.01 | 12.23 | 24 | 33603 | 2858 | 64462247 |
Respiratory rate increased | 43.99 | 12.23 | 51 | 33576 | 18280 | 64446825 |
Sleep apnoea syndrome | 43.55 | 12.23 | 65 | 33562 | 29767 | 64435338 |
Bronchospasm | 43.35 | 12.23 | 55 | 33572 | 21627 | 64443478 |
Airway peak pressure increased | 43.13 | 12.23 | 13 | 33614 | 324 | 64464781 |
Forced vital capacity decreased | 42.21 | 12.23 | 19 | 33608 | 1497 | 64463608 |
Depressed mood | 41.81 | 12.23 | 76 | 33551 | 40936 | 64424169 |
Vital capacity decreased | 41.62 | 12.23 | 17 | 33610 | 1055 | 64464050 |
Rheumatoid arthritis | 41.24 | 12.23 | 17 | 33610 | 164277 | 64300828 |
Osteoporosis | 40.41 | 12.23 | 76 | 33551 | 42004 | 64423101 |
Respiration abnormal | 39.59 | 12.23 | 30 | 33597 | 6285 | 64458820 |
Drug level increased | 39.57 | 12.23 | 67 | 33560 | 34129 | 64430976 |
Respiratory disorder | 39.48 | 12.23 | 69 | 33558 | 36042 | 64429063 |
Pulmonary function test decreased | 38.98 | 12.23 | 30 | 33597 | 6431 | 64458674 |
Joint swelling | 38.97 | 12.23 | 33 | 33594 | 215349 | 64249756 |
Bronchiectasis | 38.47 | 12.23 | 42 | 33585 | 14098 | 64451007 |
Pain | 38.14 | 12.23 | 154 | 33473 | 553357 | 63911748 |
Diarrhoea | 37.71 | 12.23 | 222 | 33405 | 722482 | 63742623 |
PCO2 increased | 37.43 | 12.23 | 18 | 33609 | 1649 | 64463456 |
Respiratory acidosis | 37.31 | 12.23 | 35 | 33592 | 9820 | 64455285 |
Infusion related reaction | 36.70 | 12.23 | 20 | 33607 | 164447 | 64300658 |
Gout | 36.15 | 12.23 | 50 | 33577 | 21363 | 64443742 |
Decreased bronchial secretion | 34.82 | 12.23 | 8 | 33619 | 65 | 64465040 |
Middle insomnia | 34.60 | 12.23 | 38 | 33589 | 12839 | 64452266 |
Increased viscosity of bronchial secretion | 34.57 | 12.23 | 12 | 33615 | 473 | 64464632 |
Affective disorder | 34.23 | 12.23 | 28 | 33599 | 6552 | 64458553 |
Intervertebral disc degeneration | 34.02 | 12.23 | 38 | 33589 | 13082 | 64452023 |
Granuloma | 34.00 | 12.23 | 28 | 33599 | 6613 | 64458492 |
Hepatic enzyme increased | 33.33 | 12.23 | 13 | 33614 | 129930 | 64335175 |
Blood immunoglobulin E increased | 32.72 | 12.23 | 22 | 33605 | 3822 | 64461283 |
Fatigue | 32.50 | 12.23 | 243 | 33384 | 748487 | 63716618 |
Multiple drug therapy | 32.30 | 12.23 | 18 | 33609 | 2236 | 64462869 |
Gastrooesophageal reflux disease | 32.19 | 12.23 | 106 | 33521 | 83037 | 64382068 |
Congestive cardiomyopathy | 32.18 | 12.23 | 33 | 33594 | 10311 | 64454794 |
Toxicity to various agents | 31.79 | 12.23 | 309 | 33318 | 363204 | 64101901 |
PO2 decreased | 31.78 | 12.23 | 19 | 33608 | 2694 | 64462411 |
Rash | 31.29 | 12.23 | 128 | 33499 | 458421 | 64006684 |
Asthmatic crisis | 30.69 | 12.23 | 16 | 33611 | 1740 | 64463365 |
Medication error | 30.40 | 12.23 | 75 | 33552 | 49891 | 64415214 |
Exercise tolerance decreased | 30.38 | 12.23 | 28 | 33599 | 7682 | 64457423 |
Blood pressure inadequately controlled | 30.32 | 12.23 | 24 | 33603 | 5360 | 64459745 |
Blood pH decreased | 30.03 | 12.23 | 22 | 33605 | 4380 | 64460725 |
Oropharyngeal candidiasis | 29.95 | 12.23 | 15 | 33612 | 1500 | 64463605 |
Systemic lupus erythematosus | 29.68 | 12.23 | 3 | 33624 | 77609 | 64387496 |
Depressive symptom | 29.61 | 12.23 | 22 | 33605 | 4474 | 64460631 |
Acute respiratory failure | 29.37 | 12.23 | 74 | 33553 | 49860 | 64415245 |
Respiratory tract inflammation | 28.88 | 12.23 | 12 | 33615 | 778 | 64464327 |
Anaemia | 28.87 | 12.23 | 101 | 33526 | 378579 | 64086526 |
Lipohypertrophy | 28.85 | 12.23 | 12 | 33615 | 780 | 64464325 |
Synovitis | 28.77 | 12.23 | 8 | 33619 | 99082 | 64366023 |
Rhinorrhoea | 28.37 | 12.23 | 82 | 33545 | 59887 | 64405218 |
Breast neoplasm | 27.95 | 12.23 | 12 | 33615 | 844 | 64464261 |
Hypercholesterolaemia | 27.62 | 12.23 | 37 | 33590 | 15336 | 64449769 |
Drug interaction | 27.00 | 12.23 | 298 | 33329 | 361785 | 64103320 |
Ligament pain | 26.71 | 12.23 | 8 | 33619 | 195 | 64464910 |
Product use issue | 26.52 | 12.23 | 24 | 33603 | 151691 | 64313414 |
Cyanosis | 26.41 | 12.23 | 44 | 33583 | 22111 | 64442994 |
Supraventricular extrasystoles | 26.30 | 12.23 | 23 | 33604 | 5892 | 64459213 |
Kyphosis | 26.07 | 12.23 | 16 | 33611 | 2377 | 64462728 |
Eosinophilic bronchitis | 25.66 | 12.23 | 9 | 33618 | 366 | 64464739 |
Drug level above therapeutic | 25.15 | 12.23 | 24 | 33603 | 6877 | 64458228 |
Heart rate increased | 25.09 | 12.23 | 110 | 33517 | 98565 | 64366540 |
Stomatitis | 24.93 | 12.23 | 13 | 33614 | 109592 | 64355513 |
Respiratory tract congestion | 24.71 | 12.23 | 36 | 33591 | 16129 | 64448976 |
Wolff-Parkinson-White syndrome | 24.64 | 12.23 | 8 | 33619 | 256 | 64464849 |
Stress cardiomyopathy | 24.32 | 12.23 | 27 | 33600 | 9230 | 64455875 |
Total lung capacity abnormal | 23.96 | 12.23 | 7 | 33620 | 156 | 64464949 |
Hypoacusis | 23.94 | 12.23 | 46 | 33581 | 25821 | 64439284 |
Treatment failure | 23.55 | 12.23 | 16 | 33611 | 116800 | 64348305 |
Cushingoid | 23.19 | 12.23 | 24 | 33603 | 7579 | 64457526 |
Death | 23.17 | 12.23 | 152 | 33475 | 482553 | 63982552 |
Adrenal suppression | 22.93 | 12.23 | 12 | 33615 | 1315 | 64463790 |
Oligoarthritis | 22.84 | 12.23 | 8 | 33619 | 324 | 64464781 |
Arrhythmia | 22.77 | 12.23 | 70 | 33557 | 52874 | 64412231 |
Sinus pain | 22.47 | 12.23 | 15 | 33612 | 2574 | 64462531 |
Obesity | 22.10 | 12.23 | 39 | 33588 | 20523 | 64444582 |
Tachyarrhythmia | 22.04 | 12.23 | 21 | 33606 | 6005 | 64459100 |
Blood bicarbonate decreased | 21.92 | 12.23 | 19 | 33608 | 4810 | 64460295 |
Thrombocytopenia | 21.92 | 12.23 | 53 | 33574 | 223748 | 64241357 |
Clonic convulsion | 21.89 | 12.23 | 11 | 33616 | 1108 | 64463997 |
Viral infection | 21.72 | 12.23 | 54 | 33573 | 36086 | 64429019 |
Therapeutic product effect decreased | 21.69 | 12.23 | 17 | 33610 | 115334 | 64349771 |
Pleural rub | 21.62 | 12.23 | 5 | 33622 | 42 | 64465063 |
Generalised tonic-clonic seizure | 21.32 | 12.23 | 57 | 33570 | 39800 | 64425305 |
Glossodynia | 21.22 | 12.23 | 4 | 33623 | 64692 | 64400413 |
Dyspnoea at rest | 21.17 | 12.23 | 21 | 33606 | 6308 | 64458797 |
Swelling | 20.87 | 12.23 | 32 | 33595 | 160186 | 64304919 |
Appetite disorder | 20.80 | 12.23 | 21 | 33606 | 6440 | 64458665 |
Intentional product use issue | 20.68 | 12.23 | 12 | 33615 | 95352 | 64369753 |
Status epilepticus | 20.64 | 12.23 | 39 | 33588 | 21624 | 64443481 |
Ventricular tachycardia | 20.38 | 12.23 | 51 | 33576 | 34214 | 64430891 |
Pancytopenia | 20.27 | 12.23 | 27 | 33600 | 143282 | 64321823 |
Hypoventilation | 20.22 | 12.23 | 20 | 33607 | 5986 | 64459119 |
Pericarditis | 20.21 | 12.23 | 4 | 33623 | 62512 | 64402593 |
Arteriosclerosis coronary artery | 20.08 | 12.23 | 32 | 33595 | 15497 | 64449608 |
Influenza | 20.07 | 12.23 | 109 | 33518 | 106422 | 64358683 |
Neuropathy peripheral | 20.05 | 12.23 | 19 | 33608 | 117506 | 64347599 |
Sputum increased | 20.03 | 12.23 | 16 | 33611 | 3619 | 64461486 |
Hypokalaemia | 19.87 | 12.23 | 120 | 33507 | 121783 | 64343322 |
Acute kidney injury | 19.81 | 12.23 | 145 | 33482 | 449095 | 64016010 |
Gastric atony | 19.68 | 12.23 | 3 | 33624 | 0 | 64465105 |
Antasthmatic drug level above therapeutic | 19.68 | 12.23 | 3 | 33624 | 0 | 64465105 |
Electrocardiogram ST segment depression | 19.38 | 12.23 | 17 | 33610 | 4372 | 64460733 |
Impaired healing | 19.28 | 12.23 | 4 | 33623 | 60469 | 64404636 |
Tonic convulsion | 19.04 | 12.23 | 12 | 33615 | 1869 | 64463236 |
Arthropathy | 19 | 12.23 | 21 | 33606 | 120946 | 64344159 |
Oesophagogastroduodenoscopy | 18.98 | 12.23 | 6 | 33621 | 176 | 64464929 |
Bronchitis chronic | 18.93 | 12.23 | 16 | 33611 | 3916 | 64461189 |
Pertussis | 18.84 | 12.23 | 9 | 33618 | 812 | 64464293 |
Eosinophilic pneumonia | 18.77 | 12.23 | 17 | 33610 | 4560 | 64460545 |
Eosinophilic pneumonia chronic | 18.43 | 12.23 | 7 | 33620 | 358 | 64464747 |
Product use in unapproved indication | 17.95 | 12.23 | 41 | 33586 | 176577 | 64288528 |
Presbyacusis | 17.86 | 12.23 | 13 | 33614 | 2562 | 64462543 |
Paranasal sinus hypersecretion | 17.86 | 12.23 | 14 | 33613 | 3082 | 64462023 |
Left ventricular failure | 17.86 | 12.23 | 22 | 33605 | 8395 | 64456710 |
Oxygen saturation decreased | 17.79 | 12.23 | 106 | 33521 | 107070 | 64358035 |
Completed suicide | 17.66 | 12.23 | 59 | 33568 | 224355 | 64240750 |
Perfume sensitivity | 17.53 | 12.23 | 8 | 33619 | 651 | 64464454 |
Drug ineffective | 17.47 | 12.23 | 321 | 33306 | 839926 | 63625179 |
Ventricular extrasystoles | 17.25 | 12.23 | 32 | 33595 | 17497 | 64447608 |
Ankle fracture | 17.25 | 12.23 | 29 | 33598 | 14681 | 64450424 |
Adjustment disorder | 17.12 | 12.23 | 13 | 33614 | 2732 | 64462373 |
Bronchitis | 17.06 | 12.23 | 106 | 33521 | 108637 | 64356468 |
Lung diffusion disorder | 16.93 | 12.23 | 5 | 33622 | 116 | 64464989 |
Pulmonary congestion | 16.86 | 12.23 | 38 | 33589 | 23842 | 64441263 |
Ventricular arrhythmia | 16.74 | 12.23 | 20 | 33607 | 7395 | 64457710 |
Allergic cough | 16.71 | 12.23 | 7 | 33620 | 463 | 64464642 |
Ocular discomfort | 16.69 | 12.23 | 15 | 33612 | 3984 | 64461121 |
Respiratory tract infection | 16.59 | 12.23 | 50 | 33577 | 37357 | 64427748 |
Glaucoma | 16.28 | 12.23 | 30 | 33597 | 16318 | 64448787 |
Macrocytosis | 16.15 | 12.23 | 12 | 33615 | 2440 | 64462665 |
Lipid metabolism disorder | 16.10 | 12.23 | 6 | 33621 | 291 | 64464814 |
Nasal septum deviation | 15.98 | 12.23 | 10 | 33617 | 1538 | 64463567 |
Nasal polyps | 15.91 | 12.23 | 14 | 33613 | 3615 | 64461490 |
Gastrointestinal disorder | 15.90 | 12.23 | 14 | 33613 | 89695 | 64375410 |
Contraindicated product prescribed | 15.86 | 12.23 | 9 | 33618 | 1158 | 64463947 |
Injection site pain | 15.74 | 12.23 | 21 | 33606 | 111387 | 64353718 |
Haemoglobin decreased | 15.54 | 12.23 | 51 | 33576 | 195012 | 64270093 |
Hyperkalaemia | 15.40 | 12.23 | 18 | 33609 | 101111 | 64363994 |
Bronchitis bacterial | 15.17 | 12.23 | 9 | 33618 | 1258 | 64463847 |
Nasal discharge discolouration | 14.84 | 12.23 | 10 | 33617 | 1744 | 64463361 |
Wound | 14.72 | 12.23 | 11 | 33616 | 76466 | 64388639 |
Deep vein thrombosis | 14.68 | 12.23 | 20 | 33607 | 105162 | 64359943 |
Lung perforation | 14.66 | 12.23 | 4 | 33623 | 69 | 64465036 |
Increased bronchial secretion | 14.58 | 12.23 | 12 | 33615 | 2830 | 64462275 |
Flail chest | 14.45 | 12.23 | 4 | 33623 | 73 | 64465032 |
Nasal oedema | 14.31 | 12.23 | 8 | 33619 | 1000 | 64464105 |
Eosinophilia | 14.24 | 12.23 | 48 | 33579 | 38028 | 64427077 |
Burns third degree | 14.24 | 12.23 | 6 | 33621 | 403 | 64464702 |
Urogenital haemorrhage | 14.24 | 12.23 | 7 | 33620 | 673 | 64464432 |
Injection site hypoaesthesia | 14.18 | 12.23 | 6 | 33621 | 407 | 64464698 |
Dermatitis allergic | 14.14 | 12.23 | 27 | 33600 | 15082 | 64450023 |
Transaminases increased | 14.11 | 12.23 | 3 | 33624 | 44591 | 64420514 |
Diabetes mellitus inadequate control | 14.03 | 12.23 | 33 | 33594 | 21288 | 64443817 |
Intentional dose omission | 14.02 | 12.23 | 16 | 33611 | 5636 | 64459469 |
Diabetes mellitus | 13.89 | 12.23 | 70 | 33557 | 66404 | 64398701 |
Hypoxia | 13.87 | 12.23 | 86 | 33541 | 88063 | 64377042 |
Seizure | 13.64 | 12.23 | 140 | 33487 | 166752 | 64298353 |
White blood cell count decreased | 13.46 | 12.23 | 40 | 33587 | 157797 | 64307308 |
Inguinal hernia repair | 13.35 | 12.23 | 5 | 33622 | 246 | 64464859 |
Respiratory alkalosis | 13.16 | 12.23 | 13 | 33614 | 3884 | 64461221 |
Postictal state | 12.98 | 12.23 | 9 | 33618 | 1644 | 64463461 |
Septic shock | 12.84 | 12.23 | 22 | 33605 | 105415 | 64359690 |
Food allergy | 12.76 | 12.23 | 18 | 33609 | 7833 | 64457272 |
Upper respiratory tract infection | 12.73 | 12.23 | 73 | 33554 | 72712 | 64392393 |
Fungal disease carrier | 12.70 | 12.23 | 5 | 33622 | 282 | 64464823 |
Crepitations | 12.64 | 12.23 | 18 | 33609 | 7897 | 64457208 |
Transient ischaemic attack | 12.58 | 12.23 | 51 | 33576 | 44131 | 64420974 |
Epidural lipomatosis | 12.56 | 12.23 | 7 | 33620 | 870 | 64464235 |
Arthralgia | 12.56 | 12.23 | 159 | 33468 | 442101 | 64023004 |
Multiple sclerosis relapse | 12.55 | 12.23 | 3 | 33624 | 41132 | 64423973 |
Labelled drug-drug interaction medication error | 12.25 | 12.23 | 32 | 33595 | 22030 | 64443075 |
None
Source | Code | Description |
---|---|---|
ATC | R03DA04 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES Xanthines |
ATC | R03DA05 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES Xanthines |
ATC | R03DA54 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES Xanthines |
ATC | R03DA55 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES Xanthines |
ATC | R03DA74 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES Xanthines |
ATC | R03DB04 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES Xanthines and adrenergics |
ATC | R03DB05 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES Xanthines and adrenergics |
FDA CS | M0023046 | Xanthines |
CHEBI has role | CHEBI:35523 | bronchodilator |
CHEBI has role | CHEBI:38147 | cardiotonic drugs |
MeSH PA | D018927 | Anti-Asthmatic Agents |
MeSH PA | D001993 | Bronchodilator Agents |
MeSH PA | D002316 | Cardiotonic Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D010726 | Phosphodiesterase Inhibitors |
MeSH PA | D020011 | Protective Agents |
MeSH PA | D058914 | Purinergic Antagonists |
MeSH PA | D058915 | Purinergic P1 Receptor Antagonists |
MeSH PA | D019141 | Respiratory System Agents |
MeSH PA | D014665 | Vasodilator Agents |
FDA EPC | N0000175790 | Methylxanthine |
CHEBI has role | CHEBI:35620 | vasodilator agents |
CHEBI has role | CHEBI:49103 | drug metabolites |
CHEBI has role | CHEBI:49167 | anti-asthmatic drugs |
CHEBI has role | CHEBI:50218 | phosphodiesterase inhibitors |
CHEBI has role | CHEBI:50846 | Immunologic factor |
CHEBI has role | CHEBI:51371 | muscle relaxants |
CHEBI has role | CHEBI:67079 | anti-inflammatory agents |
CHEBI has role | CHEBI:71232 | adenosine receptor antagonists |
CHEBI has role | CHEBI:76946 | fungal metabolites |
CHEBI has role | CHEBI:85234 | human blood serum metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Bronchospasm | indication | 4386001 | |
Disorder of lung | indication | 19829001 | DOID:850 |
Bronchitis | indication | 32398004 | DOID:6132 |
Pulmonary emphysema | indication | 87433001 | |
Asthma | indication | 195967001 | DOID:2841 |
Asthma night-time symptoms | indication | 395022009 | |
Asthma management | indication | 406162001 | |
Acute exacerbation of asthma | indication | 708038006 | |
Asthma-chronic obstructive pulmonary disease overlap syndrome | indication | 10692761000119107 | |
COPD Associated with Chronic Bronchitis | indication | ||
Chronic Obstructive Pulmonary Disease with Bronchospasms | indication | ||
Apnea in the newborn | off-label use | 13094009 | |
Neonatal Mixed Apnea | off-label use | ||
Goiter | contraindication | 3716002 | DOID:12176 |
Tachyarrhythmia | contraindication | 6285003 | |
Suicidal thoughts | contraindication | 6471006 | |
Alcoholism | contraindication | 7200002 | |
Hyperammonemia | contraindication | 9360008 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
Hyperkalemia | contraindication | 14140009 | |
Pulmonary edema | contraindication | 19242006 | DOID:11396 |
Hashimoto thyroiditis | contraindication | 21983002 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Acute tuberculosis | contraindication | 25629007 | |
Shock | contraindication | 27942005 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Depressive disorder | contraindication | 35489007 | |
Acute hepatitis | contraindication | 37871000 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Third trimester pregnancy | contraindication | 41587001 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Coronary arteriosclerosis | contraindication | 53741008 | DOID:3393 |
Multiple organ failure | contraindication | 57653000 | |
Hepatic failure | contraindication | 59927004 | |
Poisoning by phenobarbital | contraindication | 64921004 | |
Substance abuse | contraindication | 66214007 | |
Psychotic disorder | contraindication | 69322001 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Sleep apnea | contraindication | 73430006 | DOID:0050847 |
Chronic idiopathic constipation | contraindication | 82934008 | |
Cor pulmonale | contraindication | 83291003 | DOID:8515 |
Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Dermatitis herpetiformis | contraindication | 111196000 | DOID:8505 |
Seizure disorder | contraindication | 128613002 | |
Cystic fibrosis | contraindication | 190905008 | DOID:1485 |
Angina pectoris | contraindication | 194828000 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Bladder outflow obstruction | contraindication | 236645006 | |
Sepsis syndrome | contraindication | 238150007 | |
Hypocomplementemic urticarial vasculitis | contraindication | 239945009 | |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Dyspnea | contraindication | 267036007 | |
Retention of urine | contraindication | 267064002 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Continuous fever | contraindication | 271751000 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Smoking cessation assistance | contraindication | 384742004 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Breastfeeding (mother) | contraindication | 413712001 | |
Chronic myocardial ischemia | contraindication | 413844008 | DOID:3393 |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Porphyria | contraindication | 418470004 | |
Hypertensive urgency | contraindication | 443482000 | |
Smokes tobacco daily | contraindication | 449868002 | |
Severe Hypoxemia | contraindication | ||
Theophylline Toxicity | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.46 | acidic |
pKa2 | 3.01 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Enzyme | INHIBITOR | Ki | 3.85 | WOMBAT-PK | CHEMBL | |||
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | INHIBITOR | Ki | 4.11 | WOMBAT-PK | CHEMBL | |||
Adenosine receptor A1 | GPCR | ANTAGONIST | Ki | 9.22 | CHEMBL | CHEMBL | |||
Adenosine receptor A2b | GPCR | ANTAGONIST | Ki | 5.57 | CHEMBL | CHEMBL | |||
Adenosine receptor A2a | GPCR | ANTAGONIST | Ki | 9.22 | CHEMBL | CHEMBL | |||
Transmembrane domain-containing protein TMIGD3 | Unclassified | Ki | 4.06 | CHEMBL | |||||
Adenosine receptor A3 | GPCR | ANTAGONIST | Ki | 7.85 | CHEMBL | ||||
Alkaline phosphatase, tissue-nonspecific isozyme | Enzyme | Ki | 4.09 | CHEMBL | |||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Kinase | IC50 | 4.12 | CHEMBL | |||||
Adenosine receptor A2a | GPCR | Ki | 5.17 | CHEMBL | |||||
Uncharacterized protein | Enzyme | Ki | 4.11 | CHEMBL | |||||
Adenosine receptor A3 | GPCR | Ki | 4.07 | CHEMBL | |||||
Adenosine receptor A1 | GPCR | Ki | 5.42 | CHEMBL | |||||
Adenosine receptor A1 | GPCR | Ki | 5.01 | CHEMBL | |||||
Adenosine A2 receptor | GPCR | Ki | 5.88 | CHEMBL | |||||
Adenosine A2b receptor | GPCR | Ki | 4.82 | CHEMBL | |||||
Adenosine receptor | GPCR | Ki | 4.70 | CHEMBL | |||||
Heart phosphodiesterase | Enzyme | IC50 | 4.04 | CHEMBL | |||||
Adenosine A2a receptor | GPCR | Ki | 4.89 | CHEMBL | |||||
Adenosine receptor A2b | GPCR | ANTAGONIST | Ki | 5.25 | IUPHAR | ||||
Adenosine receptor A1 | GPCR | Ki | 6.15 | CHEMBL |
ID | Source |
---|---|
4018056 | VUID |
N0000146397 | NUI |
D00227 | KEGG_DRUG |
317-34-0 | SECONDARY_CAS_RN |
5897-66-5 | SECONDARY_CAS_RN |
8000-10-0 | SECONDARY_CAS_RN |
4018055 | VANDF |
4018056 | VANDF |
4018129 | VANDF |
4018130 | VANDF |
4018132 | VANDF |
C0039771 | UMLSCUI |
CHEBI:28177 | CHEBI |
TEP | PDB_CHEM_ID |
CHEMBL190 | ChEMBL_ID |
DB00277 | DRUGBANK_ID |
CHEMBL1370561 | ChEMBL_ID |
D013806 | MESH_DESCRIPTOR_UI |
2153 | PUBCHEM_CID |
413 | IUPHAR_LIGAND_ID |
C137DTR5RG | UNII |
DB01223 | DRUGBANK_ID |
10438 | RXNORM |
2086 | MMSL |
3058 | MMSL |
4172 | MMSL |
4173 | MMSL |
4175 | MMSL |
5563 | MMSL |
5564 | MMSL |
674 | MMSL |
72114 | MMSL |
72147 | MMSL |
d00142 | MMSL |
d00758 | MMSL |
000602 | NDDF |
000603 | NDDF |
000607 | NDDF |
000608 | NDDF |
111131008 | SNOMEDCT_US |
372810006 | SNOMEDCT_US |
373508009 | SNOMEDCT_US |
387431001 | SNOMEDCT_US |
45940009 | SNOMEDCT_US |
55867006 | SNOMEDCT_US |
66493003 | SNOMEDCT_US |
D000628 | MESH_DESCRIPTOR_UI |
D031210 | MESH_DESCRIPTOR_UI |
CHEMBL1200578 | ChEMBL_ID |
376 | INN_ID |
5967-84-0 | SECONDARY_CAS_RN |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
THEOPHYLLINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0820 | SOLUTION | 80 mg | ORAL | ANDA | 25 sections |
Theophylline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-4794 | SOLUTION | 80 mg | ORAL | ANDA | 25 sections |
THEOPHYLLINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-4820 | SOLUTION | 80 mg | ORAL | ANDA | 25 sections |
Theophylline in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0264-9554 | INJECTION, SOLUTION | 80 mg | INTRAVENOUS | NDA | 27 sections |
Theophylline(Anhydrous) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0486 | TABLET, EXTENDED RELEASE | 400 mg | ORAL | ANDA | 22 sections |
Theophylline(Anhydrous) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0487 | TABLET, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 22 sections |
Aminophylline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9813 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | ANDA | 12 sections |
Aminophylline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9814 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | ANDA | 12 sections |
Aminophylline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9814 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | ANDA | 12 sections |
Aminophylline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-5921 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | ANDA | 22 sections |
Aminophylline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-5922 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | ANDA | 22 sections |
Theophylline Extended Release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-1590 | TABLET, EXTENDED RELEASE | 300 mg | ORAL | ANDA | 23 sections |
Theophylline Extended Release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-2503 | TABLET, EXTENDED RELEASE | 200 mg | ORAL | ANDA | 23 sections |
Theophylline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-604 | SOLUTION | 80 mg | ORAL | ANDA | 22 sections |
Theophylline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0038 | SOLUTION | 80 mg | ORAL | ANDA | 13 sections |
ELIXOPHYLLIN | Human Prescription Drug Label | 1 | 17856-0644 | LIQUID | 80 mg | ORAL | ANDA | 21 sections |
Theophylline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-742 | TABLET, EXTENDED RELEASE | 450 mg | ORAL | ANDA | 12 sections |
Theophylline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27808-033 | SOLUTION | 80 mg | ORAL | ANDA | 13 sections |
Theophylline(Anhydrous) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29033-001 | TABLET, EXTENDED RELEASE | 400 mg | ORAL | ANDA | 22 sections |
Theophylline(Anhydrous) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29033-002 | TABLET, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 22 sections |
TheophyllineAnhydrous | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42858-701 | TABLET, EXTENDED RELEASE | 400 mg | ORAL | ANDA | 25 sections |
TheophyllineAnhydrous | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42858-702 | TABLET, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 25 sections |
Theophylline | Human Prescription Drug Label | 1 | 46708-025 | TABLET, EXTENDED RELEASE | 300 mg | ORAL | ANDA | 21 sections |
Theophylline | Human Prescription Drug Label | 1 | 46708-026 | TABLET, EXTENDED RELEASE | 450 mg | ORAL | ANDA | 21 sections |
Theophylline(Anhydrous) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-318 | TABLET, EXTENDED RELEASE | 400 mg | ORAL | ANDA | 22 sections |
Theophylline(Anhydrous) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-319 | TABLET, EXTENDED RELEASE | 600 mg | ORAL | ANDA | 22 sections |
AMINOPHYLLINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1204 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | ANDA | 12 sections |
AMINOPHYLLINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1341 | INJECTION, SOLUTION | 25 mg | INTRAVENOUS | ANDA | 12 sections |
Theo-24 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52244-100 | CAPSULE, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 25 sections |
Theo-24 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52244-200 | CAPSULE, EXTENDED RELEASE | 200 mg | ORAL | ANDA | 25 sections |